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Surfactant treatment is given on the assumption
that surfactant deficiency is the major cause of
respiratory distress syndrome (RDS). However,
we know that babies with RDS are also very
immature. They have a number of interrelated
problems which are difficult to separate from sur-
factant deficiency: difficulty clearing their lung
fluid; their lung structure is very immature; they
have a patent ductus arteriosus with relative pul-
monary hypertension and pulmonary hyperperfu-
sion; their muscle tone is poor and their ribs are
soft; they have erratic respiratory control which
is prone to apnoea; surfactant is present but in
reduced amounts with poor physical properties
and there is often a massive leak of protein on
to the alveolar surface which interferes with the
surfactant function. It is important to remember
that surfactant is only one of these problems and
therefore surfactant therapy cannot be expected
to cure RDS although it may reduce the severity
of some of the symptoms.
In 1977 we synthesized an artificial lung surfactant
composed of dipalmitoylphosphatidylcholine and
unsaturated phosphatidylglycerol, called ALEC
standing for artificial lung expanding compound
[1 — 3, 6]. This has physical properties similar to
natural surfactant when used in a crystalline state
and applied to an air-water interface, in excess, at
37 °C. We initially tested this artificial surfactant
by measuring the compliance of artificially venti-
lated 27 day fetal rabbits comparing the effect
with untreated controls and animals treated with
natural rabbit surfactant extract [8] (figure 1).
After 30 minutes ventilation the compliance was
higher in both treated groups than the controls
but highest in the natural surfactant group. How-
ever, by 60 minutes both natural and artificial
surfactant treated groups had similar values.
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Encouraged by this result, the physical properties
of the surfactant and its lack of potentially toxic
components, we started using the artificial surfac-
tant in premature babies. This was used in a study
between September 1979 and January 1982 as one
25 mg dose of powder given to resuscitated babies
at birth down the endotracheal tube [5, 7]. It was a
non-randomized, case controlled, study eventually
involving 129 babies under 35 weeks gestation.
The control babies had a mortality of 19% com-
pared qith 4% of the surfactant treated babies.
Encouraged by this result, in January 1982 be-
tween Cambridge and Nottingham we started a




Figure 1. Lung-torax compliance during artificial venti-
lation; 27 day fetal rabbits.
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randomized controlled trial with 360 babies under
34 weeks gestation to study the prophylactic effect
of ALEC suspension given at birth on respiratory
support and compliance during the first few days
of life. Babies were unselected and bora in one of
the hospitals under 35 weeks gestation. They were
randomized to surfactant or control just before
birth. ALEC powder, 50 to 100 mgs was hand
shaken with 1 ml saline at 4 °C just before delivery.
Specimens were obtained for subsequent L/S ratio
analysis. One ml of saline was the control sub-
stance. Surfactant or saline were placed in the
pharynx at birth. If the baby was intubated further
doses were given down the endotracheal tube at
10 minutes 1 hour and 24 hours. Trial treatment
was not disclosed to the clinical teams. Compli-
ance of the respiratory system was measured
where possible at 1, 6, 24, 48 hours and 7 days.
Randomized babies were excluded from the analy-
sis if they were stillborn or had gross malforma-
tions. The trial was analyzed by treatment as
randomized.
The factors which influence the outcome of pre-
mature babies are shown in table I. Three
hundred and forty-one unselected babies were
entered into the trial. Fourteen were ineligible
because they were stillborn or had major malfor-
mations. There were 163 surfactant treated and
164 controls, 69 were surfactant treated babies
and 67 were controls were under 30 weeks gesta-
tion. The data for babies under 30 weeks gestation
are shown separately or in brackets. The two
groups are reasonably well matched.
In this trial there was no apparent effect from
surfactant treatment in babies of 30 weeks gesta-
tion or more. This is because the incidence of
RDS and its complications were very low, only
1% have an IVH, PDA or die. Two thirds are
in oxygen for under 24 hours and 75% are not
ventilated. Therefore the results shown are for the
babies under 30 weeks gestation.
Compliance of the respiratory system was meas-
ured at the bedside using an oesophageal balloon
for dynamic compliance or ventilator pressure for
static compliance, and a pneumotachograph in an
endotracheal tube or facemask. Figure 2 shows
compliance measurements for babies under 30
Table I. Basic data and factors which might influence outcome; shown as percentages or mean and standard










L/S ratios were analyzed from amniotic or gastric aspirate collected at delivery.
* L/S ratios were analyzable only in 136 surfactant babies in 134 controls.







Birth weight < 30 weeks
Gestational age
Gestational age < 30 weeks
L/S ratio*
L/S ratio** < 30 weeks
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1 Hour 6 Hours 24 Hours 48 Hours 7 Days
D = SURF, m -- COHT.
« = p<0.01 m -- p<0.001
Figure 2. Compliance of the respiratory system — Cam-
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Figure 4. Average peak ventilator pressure for all the
babies less than 30 weeks gestation.
weeks gestation made at 1, 6, 24, 48 hours and 7
days. The error bars are standard error of the
mean. The open bars represent surfactant therapy
and the speckled bars controls. The numbers are
the numbers of babies measured at each time.
There is little effect at 1 hour, but significant
improvements in the surfactant treated group at
6 and 24 hours. At 48 hours and 7 days the
compliance is higher but the difference is not
significant. The compliance of the surfactant
treated babies rose rapidly in the first 6 hours to
a plateau whereas the controls improved slowly
over the first few days.
Figure 3 shows the inspired oxygen concentrations
for the two groups of babies under 30 weeks
gestation over the first 4 days of life. Note the
scale on the bottom is not linear and the error
bars are standard error of the mean. It is presented
in this way to be comparable to the data of EN-
HORNING [8]. It shows that from 6 hours the sur-
factant treated babies had inspired oxygen requi-
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Figure 3. Average inspired oxygen concentrations for all
the babies under 30 weeks gestation.
Figure 4 shows the peak inspiratory pressures for
the two groups of babies under 30 weeks gestation
over the first 4 days of life. Note the scale on the
bottom is not linear and the error bars are stan-
dard error of the mean. It shows that from 12
hours the surfactant treated babies had peak inspi-
ratory pressures significantly lower than the con-
trols.
Table II shows the incidence of complications for
babies under 30 weeks gestation. They are patent
•ductus arteriosus, pneumothorax, death at any
time while in the neonatal intensive care unit, the
need for oxygen therapy longer than 28 days, the
use of paralyzing agents during ventilator therapy
and peri ventricular hemorrhages. It shows the
numbers in each group and the percentage of each
complication with 95% confidence intervals for
the difference between the two groups. There was
no significant difference in the incidence of patent
ductus arteriosus or pneumothorax. The mortality
for the surfactant treated babies was significantly
reduced from 34% to 19%. That is 15 less deaths
per 100 babies. The 95% confidence interval is
wide with a possible effect of a reduction of 1
death to 31 fewer deaths per 100 babies. When
considering the incidence of all other complica-
tions it must be remembered that more surfactant
treated babies survived to be at risk of the compli-
cation.
There was a significant reduction in the number
of surfactant treated babies receiving prolonged
oxygen therapy. This effect was equivalent to 18
less babies per 100 with 95% confidence intervals
of 3 to 33 less receiving oxygen beyond 28 days.
The use of pancuronium was considered to be a
complication of RDS because babies with the
J. Perinat. Med. 15(1987)
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Table Π. Complications of prematurity babies < 30 weeks; incidence, mean and 95% confidence interval for the
difference.
Complication Controls Surfactant
N = 67 n = 69
Difference per 100 treated babies
(mean and 95% Cl)
Deaths in the NICU1
IVH2
Oxygen > 28 days3
Pneumothorax
Patent ductus4
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1 include death from all causes; 2 mainly diagnosed by ultrasound scan, but in babies who died early they were
found at post mortem; 3 is calculated as the incidence of 28 day survivors; 4 diagnosed from clinical criteria;
5 percentage of ventilated Cambridge babies (ALEC 48, Controls 54) who were paralyzed.
worst lung disease were paralyzed. The use of
pancuronium in the surfactant treated babies was
reduced from 52% to 27% a reduction of 25 per
100 babies with 95% confidence interval from 7
to 43 less babies being paralyzed. The incidence
of all grades of periventricular hemorrhages was
significantly reduced equivalent to 21 babies per
100 from 40% to 19% with confidence intervals
showing a possible reduction from 6 less he-
morrhages to 36 less hemorrhages per 100 babies.
Data on mortality: Babies die from a variety of
causes, not all RDS. Eighty eight per cent (21 out
of 24) of the controls died as a consequence of
RDS compared with only 50% (7 out of 14) of
the surfactant treated babies (p <0.05), showing
that the reduction in mortality was particularly
affecting RDS deaths.
Figure 5 shows the incidence of periventricular
hemorrhages for Cambridge babies. Nottingham
babies were not regularly scanned. It shows the
number of babies with hemorrhages divided into
subgroups. E is equivocal; 1 is germinal layer
hemorrhage; 2 and 3 are hemorrhages contained
within the ventricles; 4 is hemorrhage into the
brain parenchyma and PM is parenchymal he-
morrhage found at postmortem in babies who
died before they could be scanned, the numbers
of these are very small. The difference is significant












Figure 5. Periventricular hemorrhages diagnosed in the
Cambridge subgroup. They are grouped according to
the Papile classification: Ε = equivocal, 1 = grade 1,
2 = grade 2, 3 = grade 3, 4 = grade 4 and PM =
hemorrhage diagnosed at postmortem. The ρ value is
for the comparison of the numbers in the two groups.
The statistical significance for the comparison of the
numbers with grade 4 or PM is χ2 = 6.268 (ρ < 0.05).
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In May 1984 we started a second stage of this
trial [9]. The purpose was to define the effect
of artificial surfactant on the complications of
prematurity in babies between 25 and 29 weeks
gestation. Including babies of this gestation al-
ready randomized in the Cambridge-Nottingham
trial approximately 300 babies were required to
show a 25% reduction in mortality from 36% to
27% with a 75% power. This required collabor-
ation from 10 British neonatal units to produce a
quick result.
The protocol for this trial was almost identical to
the Cambridge Nottingham trial. Babies entered
the study if they were born in hospital between
25 and 29 weeks gestation. They were randomized
to surfactant or control just before birth. Rando-
mization was stratified by gestational age to pre-
vent imbalance. The strata were 25 and 26 weeks
and 27, 28 and 29 weeks. Approximately 100 mg
of surfactant powder suspended in 1 ml of cold
saline or 1 ml of saline as the control substance
were placed in the pharynx at birth. If the baby
was intubated further doses were given down the
endotracheal tube at 10 minutes 1 hour and 24
hours. The randomization and treatment were
kept secrete. Babies were retrospectively excluded
from the main analysis because they were
stillborn, grossly malformed or not resuscitated.
Analysis was for treatment groups as randomized.
Three hundred and twenty-eight babies were
entered into the trial. There were 164 in each
treatment group, 20 were ineligible. The factors
which influence the outcome of premature babies
are shown in table III. They are well matched
between the groups particularly for birthweight,
sex, labor, steroids and beta-adrenergic stimu-
lants.
RDS is the major complication of prematurity.
We developed a simple classification prior to the
trial. It is based on the number of hours a baby
receives more than 30% oxygen in the first 5 days.
Babies receiving more than 30% oxygen for under
24 hours were defined as having no RDS. Babies
receiving more than 30% oxygen for 25 to 48
hours had mild RDS. Babies in more than 30%
oxygen for 2 to 5 days had moderate RDS and
more than 5 days severe RDS. If a baby died in
the first 5 days receiving more than 30% oxygen
the RDS was graded severe.





































































































































IUGR = intrauterine growth retardation
Born infected = A baby who had bacteria growing in a blood culture taken at delivery.
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Table IV. Effect of prognostic factors on hours of ventila-
tion in the first 10 days survivors only.
None Mild Moderate Severe
Figure 6. RDS subdivided into 4 grades of severity and
shown as the percentage of ALEC or Controls in each
grade. The ALEC treated are open and controls are
stippled. The deaths in each grade are shown in black.
The numbers of babies in each grade are shown above
the block. For definition of RDS grades see the text.
The χ2 test for trend on ordered severity (0, 1, 2, 3) is
4.84 ρ < 0.03.
Figure 6 shows the RDS grades with the percent-
age of each treatment group in each grade. Surfac-
tant treated babies are represented by the open
bars and controls by the stippled bars. The deaths
in each grade are shown white. The numbers
above each bar are the numbers in each grade.
There are 159 surfactant treated babies and 149
controls. In the No RDS grade there were over
one third more surfactant treated babies than con-
trols. In the severe grade there were 29% fewer
surfactant treated babies. There is little difference
between the groups in the two intermediate gra-
des. An analysis for trend is significant at the 3%
level, showing the surfactant treated babies have
less severe RDS.
Table IV shows the effect on hours of ventilation
in the first 10 days using multiple regression analy-
sis. The first ten days were chosen as the time
when prophylactic ALEC treatment might have
most effect on respiration. Only survivors were
included even though more controls died. This
therefore gives a conservative analysis. The para-
meters taken into account were surfactant, sex,
gestational age, first or subsequent multiple births
and non-Cambridge centers. The baseline was a
control, male, singleton at 25 weeks gestation born
in Cambridge. Such a baby has an average of
183 hours ventilation in the first 10 days. The
coefficients can be added or subtracted from this
value to show the effect of each parameter. Surviv-

































Multiple regression analysis giving coefficients and stan-
dard errors with significance value. 1 week GA. means
the effect for each additional week of gestational age.
The regression coefficients are the change in hours of
support attributable to each prognostic factor in the
first 10 days.
* Baseline = male, singleton, control, 25 weeks gesta-
tion in Cambridge.
hours less ventilation in the first 10 days than the
controls. This was significant at the 5% level.
Table V shows the complications of prematurity
in the two groups. They are: all deaths in the
neonatal intensive care unit, deaths in the first
28 days of life, parenchymal brain hemorrhages
detected ultrasonically, oxygen therapy for more
than 10 days, pneumothorax or interstitial emphy-
sema, and patent ductus arteriosus and infection.
It shows the percentage for each treatment group
with 95% confidence intervals for the difference
in percentage points and the significance of that
difference. The overall mortality for the surfactant
treated babies was reduced from 30% of the con-
trols to 19%, an 11% point difference with a 95%
confidence interval from 2 to 21 fewer deaths per
100 babies. The 28 day mortality was reduced
from 27% to 14% in the surfactant treated babies,
a 13% point reduction with 95% confidence inter-
val from 4 to 22 fewer deaths per 100 babies.
When considering the incidence of all other com-
plications it must be remembered that more of the
surfactant treated babies have survived to be at
risk of the complication. The incidence of paren-
chymal brain hemorrhages was reduced from 24%
to 16% a reduction of 8 percentage points with
95% confidence interval of 1 more to 17 less
hemorrhages per 100 babies. All babies are in-
J. Perinat. Med. 15(1987)
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Table V. Complications of prematurity in the eligible babies in the two groups; percentage and 95% confidence
interval for the difference in the percentages with p values for the difference taking into account the four stata (see
analyses).
ALEC Control
N = 159 N = 149
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1 Five ALEC treated babies and 6 controls were not scanned therefore only 154 ALEC babies and 143 controls
are included.
2 As defined serious postnatal infection was after the first 24 hours, NEC does not occur in the first 24 hours. The
denominator for these was 152 ALEC treated babies and 139 controls.
3 There were 138 ALEC treated babies and 117 controls surviving 10 days.
4 Pneumothorax here refers to pneumothorax and interstitial emphysema.
eluded except for 5 surfactant treated and 6 con-
trols who were not scanned. The incidence of
other intraventricular and germinal layer he-
morrhages was 19% in each group. Forty-three
percent of surviving control babies received oxy-
gen therapy for more than 10 days compared with
36% of surfactant treated babies. There was little
difference in the incidence of pneumothoraces and
interstitial emphysem, patent ductus arteriosus or
infection.
We have now been studying the effect of artificial
surfactant in premature babies under 35 weeks
gestation since 1979. It has now been used at birth
12 large neonatal centers and 323 babies treated
with 334 controls some randomized others not.
The studies have consistently shown a reduced
mortality. Overall there has been a significant
reduction in mortality from 18.5% to 11% (p
< 0.008).
In conclusion, this artificial surfactant when given
prophylactically reduces the severity of the RDS,
the hours of ventilation and high inspired oxygen
concentrations, the incidence of parenchymal
brain hemorrhages and most significantly the
mortality. It dies not appear to have any major
harmful side effects.
I have concentrated on my own artificial surfac-
tant data. However, there are other studies using
mixtures of phospholipids, particularly from Pro-
fessor OPLADEN which show similar results, that
is RDS is not cured but the major complications
are reduced. It is interesting that the clinical results
from artificial surfactant treatment show very si-
milar results to natural surfactant treatment when
given at birth. I hope that the good results from
all the different studies will mean that in the near
future the outlook for very premature babies will
be improved.
J. Perinat. Med. 15(1987)
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Abstract
A protein-free artificial surfactant (ALEC) composed of
two phospholipids when given as a prophylactic treat-
ment at birth to very premature babies in randomized
controlled trials. It was shown to reduce the severity
of RDS, the ventilator pressure, the inspired oxygen
requirements, the compliance of the respiratory system,
the neonatal mortality and the incidence of ventricular
hemorrhage. There are no apparent side effects from
this treatment.
Keywords: Dipalmitoyliphosphatidylcholine, intraventricular hemorrhage, neonatal mortality, phosphatidylgly-
cerol, pneumothorax, premature infant, pulmonary surfactant, respiratory distress syndrome.
Zusammenfassung
Substitution mit synthetischem Surfactant beim Neugebo-
renen
1977 wurde ein künstlicher Surfactant bestehend aus
Dipalmitoylphosphatidylcholin und ungesättigten phos-
phorylierten Glycerolen mit der Bezeichnung ALEC syn-
thetisiert. Zunächst wurde die Substanz bei künstlich
beatmeten, 21 Tage alten Rattenfeten getestet. Dabei
wurde gezeigt, daß die Compliance der Beatmungsein-
heit 30 und 60 Minuten nach Applikation signifikant
verbessert war. Dann wurde eine fallkontrollierte Studie
mit 129 Kindern unterhalb der 30. Schwangerschaftswo-
che durchgeführt und 25 mg als Trockensubstanz in den
Tubus gleich bei der Intubation post partum gegeben.
In der Kontrollgruppe lag die Mortalität bei 19% vergli-
chen mit 4% in der Surfactantgruppe.
Im Januar 1982 haben wir mit einer randomisierten
Versuchsreihe, die 360 Kinder unterhalb der 34. Schwan-
gerschaftswoche umfaßte, begonnen. Noch vor der Ge-
burt wurden die Kinder der Surfactant- bzw. der Kon-
trollgruppe zugeordnet. Kurz vor der Entbindung wurde
die Trockensubstanz in l ml Kochsalz bei 4 °C aufgelöst;
in der Kontrollgruppe wurde nur Kochsalz verwendet.
Die Surfactantlösung bzw. das Kochsalz wurden bei
Geburt in den Pharynx gegeben. Wurden die Kinder
intubiert, gaben wir weitere Dosen nach 10 min, l h
und 24 h. Die Compliance der Beatmungseinheit wurde,
wenn möglich nach l h, 6 h, 24 h, 48 h und 7 d gemessen.
In der Versuchsreihe waren schließlich 163 mit Surfac-
tant behandelte und 164 Kontrollkinder. Bei Kindern
oberhalb der 30. Woche zeigte sich kein Einfluß durch
die Surfactantbehandlung; in dieser Gruppe traten ein
RDS und dadurch bedingte Komplikationen sehr selten
auf.
Von größerer Bedeutung ist die Surfactantbehandlung
bei Kindern unterhalb der 30. Woche. Hier war die
Compliance des Beatmungssystems nach 6 bzw. 24h
deutlich besser. Der Ch-Gehalt in der Einatmungsluft
war in der Surfactantgruppe ab der 6. Lebensstunde
signifikant niedriger. Ab der 12. Lebensstunde waren
auch die Maxima beim Inspirationsdruck signifikant
geringer. In bezug auf einen offenen Ductus arteriosus
oder einen Pneumothorax gab es keine signifikanten
Unterschiede. In der Surfactantgruppe war die Mortali-
tät von 34% auf 19% reduziert. Die Inzidenz von Ventri-
kelblutungen sank von 40% auf 19%, und die Anzahl
der Kinder, die länger als 28 Tage Sauerstoff benötigten,
sank von 35% auf 20%. Auch der Pancuroniumbedarf
war in der Surfactantgruppe deutlich geringer.
Im Mai 1984 wurde der Versuch erweitert. Es sollte
der Einfluß des synthetischen Surfactant auf die durch
Frühgeburtlichkeit bedingten Komplikationen bei Kin-
dern zwischen der 25. und 29. Woche bestimmt werden.
10 Zentren beteiligten sich. Abgesehen davon, daß jetzt
nur Kinder zwischen der 25. und 29. Woche berücksich-
tigt wurden, war die Protokollierung mit der des ersten
Versuchs identisch. Das Kollektiv umfaßte 328 Kinder.
Bezüglich der Inzidenz eines RDS gab es deutliche Un-
terschiede; in der Kontrollgruppe betrug sie 36%, in der
Surfactantgruppe 25%. Ein schweres RDS trat bei 45%
der Kontrollkinder und bei 32% der Surfactantkinder
auf. Die multiple Regressionsanalyse zeigte, daß die An-
zahl der Kinder, die in den ersten 10 Lebenstagen beat-
met werden mußten, nach Surfactantbehandlung deut-
lich reduziert war. In dieser multizentrischen Untersu-
chung war die neonatale Mortalität von 30% auf 19%
reduziert; legt man die gesamten neonatalen Todesfalle
zugrunde, gab es einen Abfall von 27% auf 14%. Paren-
chymatöse Hirnblutungen sanken von 24% auf 16%.
Keine Unterschiede traten auf hinsichtlich eines Pneu-
mothorax, eines offenen Ductus arteriosus und der Beat-
mungsdauer bei mehr als 10 Tagen.
Seit 1979 untersuchen wir nun den Einfluß von syntheti-
schem Surfactant auf Frühgeborene unterhalb der 35.
Woche. Die Substanz wurde in 12 großen neonatalen
Zentren eingesetzt. 323 Kinder wurden mit Surfactant
behandelt und mit 334 Kontrollkindern verglichen. Ins-
gesamt wurde eine Senkung der Mortalität von 18.5%
auf 11% erreicht.
Zusammenfassend senkt die prophylaktische Surfactant-
gabe den Schweregrad eines RDS, die Beatmungsdauer
und die inspiratorische Ch-Konzentration sowie die Inzi-
denz von Parenchymblutungen im Gehirn, die Mortali-
tät und die Compliance des Beatmungssystems. Es sind
keine ernsthaften Nebenwirkungen bekannt.
Schlüsselwörter: Dipalmitoylphosphatidylcholin, Frühgeborenes, intraventrikuläre Blutung, Lungensurfactant,
neonatale Mortalität, Phosphatidylglycerol, Pneumothorax, RDS.
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Resume
Substitution de surfactant chez le nouveau-ne par applica-
tion de surfactant artificiel
En 1977 a etc synthetise un surfactant artificiel compose
de dipalmitylephosoptidy choline, un glycerol phospho-
ryle insature appele ALEC. Ce surfactant artificiel a des
proprietes similaires ä celles du surfactant naturel. II a
etc teste initialement chez des foetus se lapin de 27 jours
ventiles artificiellement et a montre une amelioration
significative de la compliance du Systeme respiratoire a
30 et a 60 minutes. Le surfactant a etc initialement utilise
dans une etude contrölee comportant 129 nouveaux-nes
de moins de 30 semaines de gestation a la dose unique
de 25 mg de poudre instillee dans la sonde d'intubation,
ä la naissance. Dans cette etude les enfants temoins ont
eu une mortalite de 19% en comparaison d'une mortalite
de 4% chez les enfants traites par surfactant.
En Janvier 1982, une essai controle randomise concer-
nant 360 enfants de moins de 34 semaines de gestation
a etc debute. Les enfants etaient randomises pour le
surfactant ou comme temoin juste avant la naissance.
La poudre de surfactant etait melangee ä la main avec
1 ml de serum sale a 4 °C juste avant 1'accouchement.
Comme substance temoin 1 ml de serum sale etait utilise.
A la naissance le surfactant ou le serum sale etait place
au niveau du pharynx. Si Fenfant etait intube d'autres
doses etaient donnees ä 10 minutes, une heure et ä 24
heures. Si possible, la compliance du Systeme respiratoire
etait mesuree ä 1, 6, 24, 48 heures et 7 jours. Dans cet
essai, il u a eu 163 enfants traites par surfactant et 164
temoins. II n' y a pas eu des effets apparent secondaire
au traitement par surfactant chez les enfants de 30 semai-
nes de gestation ou plus car Fincidence du SDR et de
ses complications est tres faible dans ce groupe.
Tous les effets significatifs du traitement par le surfactant
ont ete observes chez les enfants de moins de 30 semai-
nes. La compliance du Systeme respiratoire a ete amelio-
ree de fagon significative 6 heures et 24 heures apres
le traitement. La concentration d'oxygene inspire etait
significativement inferieure dans le groupe d'enfants trai-
tes par surfactant des 6 heures de vie. Le pic de pression
inspiratoires etait significativement inferieur dans le
groupe traite par surfactant des 12 heures de vie. II n'y
a pas eu de difference significative en ce qui concerne
les canaux arteriels patents et les pneumothorax. La
mortalite du groupe surfactant a ete significativement
diminuee de 34% a 19%. II y a eu une reduction signifi-
cative de la survenue d'hemorragies ventriculaires de
40% ä 19%. Le nombre d'enfant necessitant de Foxy-
gene pendant plus de 28 jours a ete diminue de 35% a
20%. II y a egalement eu une reduction significative de
l'utilisation de Pancuronium dans le groupe surfactant.
En mai 1984, cet essai a ete etendu ä un essai de second
ordre dont Fobjectif etait de definir les effets du surfac-
tant artificiel sur les complications de la prematurite
chez les enfants entre 25 et 29 semaines de gestation.
Cet essai comprenait les enfants de 10 centres. Le proto-
cole de cet essai etait ä peu pres identique a Fessai
precedent a Fexception du fait que les enfants entraient
dans Fetude s'ils etaient entre 25 et 29 semaines de
gestation. 328 enfants sont entres dans cet essai. L'inci-
dence du syndrome de detresse respiratoire a ete signifi-
cativement modifiee, avec 36% de temoin sans SDR en
comparaison de 25% des traites par surfactant, de plus
45% des temoins ont presente un SDR grave, contre
32% des enfants traites par surfactant. En utilisant une
analyse a regressions multiples, le nombre d'heures de
ventilation des enfants au cours des 10 premiers jours
de vie a ete significativement diminue par le traitement
surfactant. Dan cet essai multicentrique, la mortalite
neonatale a ete diminuee de 30% ä 19%, le nombre
total de morts neonatales de 27% a 14%, Fincidence
des hemorrhagies cerebrates parenchymateuses de 24%
ä 16%. II n'y a pas eu de reduction significative des
penumothorax, ni des canaux artificiels patents ni de la
duree d'oxygene de plus de 10 jours.
Nous sommes maintenant en train d'etudier Feffet du
surfactant artificiel chez les prematures de moins de 35
semaines depuis 1979. II a maintenant ete utilise ä la
naissance dans 12 grands centres neonataux, 323 enfants
ont ete traites par le surfactant, en comparaison de 334
temoins. Les etudes ont montre de fa$on consistante une
diminution de la mortalite. Globalement, la diminution
de la mortalite est significative, eile passe de 18,5% a
11%.
En conclusion, le surfactant artificiel lorsqu'il est fourni
en prophylaxie, diminue la severite du SDR, le nombre
d'heures de ventilation et la concentration d'oxygene
inspire, Fincidence des hemorrhagies cerebrales paren-
chymateuses, la mortalite et la compliance du Systeme
respiratoire. II n'est pas apparu qu'il presente des effets
secondaires nocifs majeurs.
Mots-cles: Dipalmitoyliphosphatidylcholine, hemorragie ventriculaire, mortalite neonatale, phosphatidylglycerol,
pneumothorax, premature, surfactant pulmonaire, syndrome de detresse respiratoire.
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